Even in high-stakes therapies, adherence is not guaranteed. This report uncovers the real challenges behind treatment persistence—and what Patient Support Programs (PSPs) and pharma leaders can do to intervene before patients drop off.
Traditional adherence metrics do not tell the full story.
Patients on rare and specialty therapies face complex barriers—treatment fatigue, financial stress, side effects, and a lack of perceived benefit. Without the right insights, PSPs and Market Access teams struggle to deliver the right interventions at the right time.
This report, powered by real-world adherence data, uncovers the biggest challenges facing patient persistence and actionable strategies for improving support programs.
Inside this report, you will learn:
- Which rare and chronic disease categories have the highest non-adherence rates
- How treatment burden, financial toxicity, and delayed symptom relief impact persistence
- Why traditional refill tracking misses key drop-off risks and what better data can reveal
- The intervention strategies that PSPs and Market Access teams can implement today
Get exclusive, data-driven insights to improve therapy persistence and patient outcomes.
